Biospecimens Core (Core-1) Director: Ahmet Dogan, MD, PhD CORE SUMMARY The Biospecimen Core will support the Memorial Sloan Kettering Cancer Center (MSK) SPORE in Lymphoma, which focuses on diffuse large B-cell lymphoma (DLBCL). The overall goal of the Biospecimen core is to provide SPORE investigators with well-characterized biological specimens, including tissues, tissue derivatives, and blood, essential for achieving the aims of the projects. The Biospecimen Core will coordinate tissue acquisition and distribution of high-quality biospecimens by experienced lymphoma pathologists. This shared resource for SPORE investigators will allow for expanding correlative studies, interrogating specific oncogenic signaling pathways, genetic alterations, and biomarker identification.
The Aims of the Biospecimen Core are:
Aim 1. To collect, process, bank, and distribute biospecimens from patients with DLBCL to SPORE investigators and collaborators in support of their research projects.
Aim 2. To provide comprehensive diagnostic characterization of lymphoma specimens collected from patients enrolled on SPORE clinical trials.
Aim 3. To process and perform integral and integrated biomarker analysis on biospecimens collected from patients enrolled on SPORE clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA192937-01A1
Application #
8997368
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2016-08-30
Project End
2021-07-31
Budget Start
2016-08-30
Budget End
2017-07-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Mondello, Patrizia; Derenzini, Enrico; Asgari, Zahra et al. (2017) Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget 8:14017-14028
Jiang, Yanwen; Ortega-Molina, Ana; Geng, Huimin et al. (2017) CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discov 7:38-53
Younes, A; Hilden, P; Coiffier, B et al. (2017) International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 28:1436-1447
Guo, A; Lu, P; Lee, J et al. (2017) HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene 36:3441-3449
Giulino-Roth, Lisa; van Besien, Herman J; Dalton, Tanner et al. (2017) Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Mol Cancer Ther 16:1779-1790
Oricchio, Elisa; Katanayeva, Natalya; Donaldson, Maria Christine et al. (2017) Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Sci Transl Med 9:
Grommes, Christian; Younes, Anas (2017) Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. Cancer Cell 31:731-733
Grommes, Christian; Pastore, Alessandro; Palaskas, Nicolaos et al. (2017) Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov 7:1018-1029
Zhang, Jiyuan; Vlasevska, Sofija; Wells, Victoria A et al. (2017) The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov 7:322-337
Younes, Anas; Berdeja, Jesus G; Patel, Manish R et al. (2016) Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol 17:622-31

Showing the most recent 10 out of 17 publications